Alembic launches Theophylline ER tablets

BRIDGEWATER, N.J. — Alembic Pharmaceuticals launched its Theophylline ER on Friday. The launch of the chronic obstructive pulmonary disease and asthma treatment is the company’s 11th launch since October. 

 

The drug will be available in 300- and 450-mg dosage strengths. 

 

“We are very excited about the launch of Theophylline ER Tablets and the opportunity to provide patients this product which serves an important unmet market need,” Alembic’s president U.S. operations Craig Salmon said.